• Moderna published its Science Day 2026 medical research presentation outlining its mRNA platform, built on chemistry, sequence engineering, targeting elements.
• Slides highlight three established modalities as near-term value drivers: infectious disease vaccines, personalized cancer vaccine intismeran autogene, rare disease therapeutics.
• Key upcoming catalysts flagged include U.S. flu vaccine approval, norovirus Phase 3 data, event-driven Phase 3 adjuvant melanoma data, PA registrational study data.
• Presentation also details mRED as the engine for Horizon 2 and 3 programs, using AI to speed decisions and move new modalities to clinical proof-of-concept.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.